452 related articles for article (PubMed ID: 18705754)
1. Plasma malondialdehyde levels and opiate withdrawal signs observed in rats treated with morphine plus naloxone: effects of alpha-lipoic acid administration.
Pinelli A; Cighetti G; Trivulzio S
Fundam Clin Pharmacol; 2008 Aug; 22(4):439-45. PubMed ID: 18705754
[TBL] [Abstract][Full Text] [Related]
2. Quantitative evaluation of opioid withdrawal signs in rats repeatedly treated with morphine and injected with naloxone, in the absence or presence of the antiabstinence agent clonidine.
Pinelli A; Trivulzio S
J Pharmacol Toxicol Methods; 1997 Nov; 38(3):117-31. PubMed ID: 9523765
[TBL] [Abstract][Full Text] [Related]
3. [The potential antinarcotic effects of guanfacine].
Marusov IV; Bogdanov EG; Marusova IB
Eksp Klin Farmakol; 1996; 59(3):24-7. PubMed ID: 8974578
[TBL] [Abstract][Full Text] [Related]
4. [The discriminative stimulus properties of naloxone during dissociative learning in a Y maze in morphine-dependent rats].
Bespalov AIu; Medvedev IO; Dravolina OA; Zvartau EE
Zh Vyssh Nerv Deiat Im I P Pavlova; 1999; 49(1):96-105. PubMed ID: 10330710
[TBL] [Abstract][Full Text] [Related]
5. Morphine withdrawal-induced c-fos expression in the heart: a peripheral mechanism.
González-Cuello A; Milanés MV; Castells MT; Laorden ML
Eur J Pharmacol; 2004 Mar; 487(1-3):117-24. PubMed ID: 15033383
[TBL] [Abstract][Full Text] [Related]
6. Quantitative opioid withdrawal signs in rats: effects exerted by clothiapine administration.
Pinelli A; Trivulzio S; Ciapponi PM
Fundam Clin Pharmacol; 1997; 11(4):346-55. PubMed ID: 9263765
[TBL] [Abstract][Full Text] [Related]
7. [The effect of GABA-positive agents on the formation of morphine dependence and on the manifestations of a withdrawal syndrome].
Belozertseva IV; Andreev BV
Eksp Klin Farmakol; 2000; 63(1):19-23. PubMed ID: 10763104
[TBL] [Abstract][Full Text] [Related]
8. The dopamine release inhibitor CGS 10746B blocks conditioned physical signs of morphine withdrawal.
Rodríguez-Arias M; Aguilar MA; Miñarro J
Addict Biol; 2003 Jun; 8(2):167-72. PubMed ID: 12850775
[TBL] [Abstract][Full Text] [Related]
9. Intra-administration associations and withdrawal symptoms: morphine-elicited morphine withdrawal.
McDonald RV; Siegel S
Exp Clin Psychopharmacol; 2004 Feb; 12(1):3-11. PubMed ID: 14769091
[TBL] [Abstract][Full Text] [Related]
10. Changes in dopaminergic neurotransmission do not alter somatic or motivational opiate withdrawal-induced symptoms in rats.
Caillé S; Rodriguez-Arias M; Minarro J; Espejo EF; Cador M; Stinus L
Behav Neurosci; 2003 Oct; 117(5):995-1005. PubMed ID: 14570549
[TBL] [Abstract][Full Text] [Related]
11. Effects of ondansetron administration on opioid withdrawal syndrome observed in rats.
Pinelli A; Trivulzio S; Tomasoni L
Eur J Pharmacol; 1997 Dec; 340(2-3):111-9. PubMed ID: 9537805
[TBL] [Abstract][Full Text] [Related]
12. Effects of tizanidine administration on precipitated opioid withdrawal signs in rats.
Pinelli A; Trivulzio S; Spezia R
Drug Alcohol Depend; 1998 Mar; 50(1):81-8. PubMed ID: 9589275
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms in dizocilpine-induced attenuation of development of morphine dependence: an association with cortical Ca2+/calmodulin-dependent signal cascade.
Hamdy MM; Noda Y; Miyazaki M; Mamiya T; Nozaki A; Nitta A; Sayed M; Assi AA; Gomaa A; Nabeshima T
Behav Brain Res; 2004 Jul; 152(2):263-70. PubMed ID: 15196794
[TBL] [Abstract][Full Text] [Related]
14. A neuroactive steroid, dehydroepiandrosterone sulfate, prevents the development of morphine dependence and tolerance via c-fos expression linked to the extracellular signal-regulated protein kinase.
Ren X; Noda Y; Mamiya T; Nagai T; Nabeshima T
Behav Brain Res; 2004 Jul; 152(2):243-50. PubMed ID: 15196791
[TBL] [Abstract][Full Text] [Related]
15. Opiate withdrawal-induced hyposensitivity to naloxone's effects on serum luteinizing hormone in the male rat.
Cicero TJ; Aleem A; Meyer ER; Schmoeker PF; Miller BT
J Pharmacol Exp Ther; 1986 Sep; 238(3):1063-70. PubMed ID: 3528453
[TBL] [Abstract][Full Text] [Related]
16. Chronic very low dose naltrexone administration attenuates opioid withdrawal expression.
Mannelli P; Gottheil E; Peoples JF; Oropeza VC; Van Bockstaele EJ
Biol Psychiatry; 2004 Aug; 56(4):261-8. PubMed ID: 15312814
[TBL] [Abstract][Full Text] [Related]
17. Modification of the development of acute opiate tolerance by increased dopamine receptor sensitivity.
Martin JR; Takemori AE
J Pharmacol Exp Ther; 1987 Apr; 241(1):48-55. PubMed ID: 3572795
[TBL] [Abstract][Full Text] [Related]
18. Mechanical allodynia and thermal hyperalgesia upon acute opioid withdrawal in the neonatal rat.
Sweitzer SM; Allen CP; Zissen MH; Kendig JJ
Pain; 2004 Jul; 110(1-2):269-80. PubMed ID: 15275777
[TBL] [Abstract][Full Text] [Related]
19. Diltiazem inhibits naloxone-precipitated and spontaneous morphine withdrawal in rats.
Kishioka S; Inoue N; Nishida S; Fukunaga Y; Yamamoto H
Eur J Pharmacol; 1996 Nov; 316(1):7-14. PubMed ID: 8982643
[TBL] [Abstract][Full Text] [Related]
20. A non-invasive gating device for continuous drug delivery that allows control over the timing and duration of spontaneous opiate withdrawal.
Azar MR; Ahmed SH; Lintz R; Gutierrez T; Stinus L; Koob GF
J Neurosci Methods; 2004 May; 135(1-2):129-35. PubMed ID: 15020097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
